107 related articles for article (PubMed ID: 20307198)
1. Combination of fludarabine and imatinib induces apoptosis synergistically through loss of mitochondrial membrane potential and increases in caspase-3 enzyme activity in human K562 chronic myleloid leukemia cells.
Baran Y; Oztekin C; Bassoy EY
Cancer Invest; 2010 Jul; 28(6):623-8. PubMed ID: 20307198
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
4. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ
Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456
[TBL] [Abstract][Full Text] [Related]
5. Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-delta.
Kurosu T; Tsuji K; Kida A; Koyama T; Yamamoto M; Miura O
Oncogene; 2007 May; 26(21):2975-87. PubMed ID: 17130834
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
Yu C; Rahmani M; Almenara J; Subler M; Krystal G; Conrad D; Varticovski L; Dent P; Grant S
Cancer Res; 2003 May; 63(9):2118-26. PubMed ID: 12727828
[TBL] [Abstract][Full Text] [Related]
7. Combination treatment of imatinib-sensitive and -resistant BCR-ABL-positive CML cells with imatinib and farnesyltransferase inhibitors.
Radujkovic A; Topaly J; Fruehauf S; Zeller WJ
Anticancer Res; 2006; 26(3A):2169-77. PubMed ID: 16827161
[TBL] [Abstract][Full Text] [Related]
8. Imatinib-induced apoptosis: a possible link to topoisomerase enzyme inhibition.
Baran Y; Zencir S; Cakir Z; Ozturk E; Topcu Z
J Clin Pharm Ther; 2011 Dec; 36(6):673-9. PubMed ID: 21105880
[TBL] [Abstract][Full Text] [Related]
9. Modulation of caspase-independent cell death leads to resensitization of imatinib mesylate-resistant cells.
Lavallard VJ; Pradelli LA; Paul A; Bénéteau M; Jacquel A; Auberger P; Ricci JE
Cancer Res; 2009 Apr; 69(7):3013-20. PubMed ID: 19318579
[TBL] [Abstract][Full Text] [Related]
10. Sorbitol-induced apoptosis of human leukemia is mediated by caspase activation and cytochrome c release.
Marfè G; Morgante E; Di Stefano C; Di Renzo L; De Martino L; Iovane G; Russo MA; Sinibaldi-Salimei P
Arch Toxicol; 2008 Jun; 82(6):371-7. PubMed ID: 18046541
[TBL] [Abstract][Full Text] [Related]
11. STI571 and morpholine derivative of doxorubicin collaborate in inhibition of K562 cell proliferation by inducing differentiation and mitochondrial pathway of apoptosis.
Jakubowska J; Wasowska-Lukawska M; Czyz M
Eur J Pharmacol; 2008 Oct; 596(1-3):41-9. PubMed ID: 18782571
[TBL] [Abstract][Full Text] [Related]
12. LLL-3, a STAT3 inhibitor, represses BCR-ABL-positive cell proliferation, activates apoptosis and improves the effects of Imatinib mesylate.
Mencalha AL; Du Rocher B; Salles D; Binato R; Abdelhay E
Cancer Chemother Pharmacol; 2010 May; 65(6):1039-46. PubMed ID: 19701750
[TBL] [Abstract][Full Text] [Related]
13. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.
Chen R; Gandhi V; Plunkett W
Cancer Res; 2006 Nov; 66(22):10959-66. PubMed ID: 17108134
[TBL] [Abstract][Full Text] [Related]
14. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells.
Yu C; Krystal G; Dent P; Grant S
Clin Cancer Res; 2002 Sep; 8(9):2976-84. PubMed ID: 12231544
[TBL] [Abstract][Full Text] [Related]
15. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH
Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346
[TBL] [Abstract][Full Text] [Related]
16. Methyl-β-cyclodextrin induces programmed cell death in chronic myeloid leukemia cells and, combined with imatinib, produces a synergistic downregulation of ERK/SPK1 signaling.
Yan J; Li QF; Wang LS; Wang H; Xiao FJ; Yang YF; Wu CT
Anticancer Drugs; 2012 Jan; 23(1):22-31. PubMed ID: 21857502
[TBL] [Abstract][Full Text] [Related]
17. Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells.
Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
Exp Cell Res; 2009 Jul; 315(11):1809-18. PubMed ID: 19268463
[TBL] [Abstract][Full Text] [Related]
18. Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib.
La Rosée P; Jia T; Demehri S; Härtel N; de Vries P; Bonham L; Hollenback D; Singer JW; Melo JV; Druker BJ; Deininger MW
Clin Cancer Res; 2006 Nov; 12(21):6540-6. PubMed ID: 17085669
[TBL] [Abstract][Full Text] [Related]
19. Apoptotic effects of resveratrol, a grape polyphenol, on imatinib-sensitive and resistant K562 chronic myeloid leukemia cells.
Can G; Cakir Z; Kartal M; Gunduz U; Baran Y
Anticancer Res; 2012 Jul; 32(7):2673-8. PubMed ID: 22753725
[TBL] [Abstract][Full Text] [Related]
20. (-)Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells.
Meng Y; Li Y; Li J; Li H; Fu J; Liu Y; Liu H; Chen X
Leuk Lymphoma; 2007 Nov; 48(11):2204-12. PubMed ID: 17926190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]